We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+39.74%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$210M
AUM Growth
+$79.2M
Cap. Flow
+$42M
Cap. Flow %
19.96%
Top 10 Hldgs %
63.23%
Holding
36
New
15
Increased
9
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$9.59M
2
ARVN icon
Arvinas
ARVN
+$5.57M
3
CBAY
Cymabay Therapeutics
CBAY
+$5.5M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$5.47M
5
DERM
Dermira, Inc.
DERM
+$5.31M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$6.31M
2
CEMI
Chembio diagnostics, Inc.
CEMI
+$2.24M
3
VCYT icon
Veracyte
VCYT
+$1.16M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$728K
5
OTLK icon
Outlook Therapeutics
OTLK
+$15K

Sector Composition

Rank Sector Weight
1 Healthcare 84.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTNT
26
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.52M 1.2%
+7,000
New +$2.46M
AMRN
27
Amarin Corp
AMRN
$297M
$1.82M 0.86%
4,375
-17,500
-80% -$6.31M
GOSS icon
28
Gossamer Bio
GOSS
$84.9M
$1.3M 0.62%
+60,000
New +$1.25M
ALLK
29
DELISTED
Allakos
ALLK
$547K 0.26%
+13,500
New +$546K
STRO icon
30
Sutro Biopharma
STRO
$416M
$518K 0.25%
4,550
– –
CEMI
31
DELISTED
Chembio diagnostics, Inc.
CEMI
$231K 0.11%
41,667
-345,500
-89% -$2.24M
BCRX icon
32
BioCryst Pharmaceuticals
BCRX
$2.24B
$204K 0.1%
25,000
– –
NVAX icon
33
PUT
Novavax
NVAX
$1.22B
$138K 0.07%
+12,500
New +$395K
OTLK icon
34
Outlook Therapeutics
OTLK
$171M
– –
-182
Closed -$15K
XBI icon
35
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
– –
-100,000
Closed -$7.17M
IMMU
36
PUT
DELISTED
Immunomedics Inc
IMMU
– –
-400,000
Closed -$5.71M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Acuta Capital Partners held 36 positions worth $210M, up 60% from $131M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners deployed $42M of net new capital in Q1 2019, opening 15 new positions and adding to 9 existing holdings. Its largest new stake was Insmed: 370,000 shares worth $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier.

On the sell side, the largest reduction was Amarin Corp, an estimated $6.31M trimmed.

  • Acuta Capital Partners's largest Q1 2019 buy was Insmed: 370,000 shares worth $10.8M.
  • Acuta Capital Partners added most to ViewRay, Inc. in Q1 2019, an estimated $3.88M increase.
  • Acuta Capital Partners's biggest Q1 2019 reduction was Amarin Corp, cutting an estimated $6.31M.
  • Acuta Capital Partners fully exited Outlook Therapeutics in Q1 2019, selling an estimated $15K.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $210M portfolio in Q1 2019.
  • Acuta Capital Partners opened 15 new positions and closed 3 in Q1 2019.
  • Acuta Capital Partners's portfolio value rose 60% quarter-over-quarter to $210M.

Based on Acuta Capital Partners's 13F filing for Q1 2019, filed 14 May 2019.